Although GLP‐1 RAs such as liraglutide, exenatide, and semaglutide showed potential for improving mental health outcomes—particularly depressive symptoms, anhedonia, anxiety, and quality of life—these preliminary signals require confirmation through larger, methodologically rigorous trials. The gene discussed is GLP1R; the disease is Anxiety.